

# 5.08



Novogen has recently achieved significant advances in its pharmaceutical research and development programs utilising its isoflavonoid technology platform.

Novogen's intellectual property has evolved from its identification of naturally occurring isoflavones in legumes to the development of synthetic compounds which are potent bio-regulators in human cells offering promise in preventing degenerative disease. This has led to a pipeline of isoflavonoid compounds that are grouped in the categories - anti-cancer, cardiovascular and anti-inflammatory. Novogen also has glucan technology under development for wound management.

From a corporate perspective: Novogen is developing compounds for the anti-inflammatory and cardiovascular areas; the 72 per cent owned subsidiary Marshall Edwards, Inc., is focused on clinical development for anti-cancer; and the 81 per cent owned company Glycotex, Inc., is focused on the discovery and development of therapies intended to accelerate wound healing and tissue repair.

This newsletter outlines recent developments in each of these areas and further details are available in market announcements at [www.novogen.com](http://www.novogen.com)

#### Two recent achievements for Novogen's anti-inflammatory compound, NV-52 are:

- published in *Expert Opinion*, peer reviewed research has confirmed NV-52 potential usefulness for the maintenance of remission in inflammatory bowel disease (IBD)
- A Phase II clinical trial is planned for IBD

## Novogen's Anti-inflammatory research progresses

In *Expert Opinion*, lead author, Laurence Howes, Professor of Pharmacology and Therapeutics at Griffith and Bond University Medical School in Queensland, said: "Improved maintenance therapy remains the greatest unmet medical need in treating Inflammatory Bowel Disease (IBD), with the challenge in drug development being a non-toxic agent that will maintain disease remission. Our research suggests that NV-52 will be a safe and well-tolerated therapy and animal studies provide promise that it may have useful efficacy".

IBD comprises two different syndromes: ulcerative colitis, which involves the rectum and colon; and Crohn's disease in which any portion of the gastrointestinal tract may be affected. There is no cure for IBD and current medical therapies have unpleasant side effects. It is estimated that over 60,000 Australians and up to 1.5 million people in the USA live with IBD.

A planned Phase II human clinical trial in IBD will be conducted at the Mater Hospital in Brisbane, under the direction of the Director of Gastroenterology, Professor Timothy Florin.

## Novogen's Cardiovascular program

Novogen's lead compound in cardiovascular research is NV-27, which has been designed to reduce restenosis. Restenosis is the re-blocking of arteries after surgery. The insertion of artificial stents is commonly used in cardiovascular surgery to clear these blockages.

A phase 1 trial has just been fully enrolled and was conducted in association with Bond University, Queensland.

## Marshall Edwards Inc - phenoxodiol and triphendiol

**Phenoxodiol** received endorsement from leading cancer researchers at the October, 2007 symposium on platinum resistant ovarian cancer held at the European Society for Gynecological Oncology in Berlin. A number of speakers confirmed the need for an effective chemosensitising drug to support new platinum treatment regimens in resistant ovarian cancer. Leading cancer researchers speaking at the symposium described advances in platinum therapies and expressed enthusiasm for phenoxodiol as a promising new investigational drug as part of a new approach for this indication.

Professor Hani Gabra of the Ovarian Cancer Action Research Centre, Imperial College London who chaired the symposium said: "Already phenoxodiol has shown promise in improved platinum responses in Phase II studies. A major multinational Phase III study, the OVATURE trial, is now underway in over 60 centres around the world, and we are excited to be part of this study".

Marshall Edwards is also progressing under licence Novogen's second anti-cancer clinical program with **triphendiol**, a derivative of phenoxodiol.

In recent months triphendiol has been granted "orphan drug" status by the US pharmaceutical regulator, the Food and Drug Administration (FDA), for three indications - pancreatic cancer, bile duct cancer and Stage IIb-IV late stage malignant melanoma.

An orphan drug refers to a product that is intended for use in a disease or condition that affects fewer than 200,000 individuals in the United States. Achieving orphan drug status is a significant boost in terms of independent recognition of the effectiveness of the drug, attracting additional FDA support and enhancing potential commercial outcomes.

Regarding the three types of cancer triphendiol is targeting:

- pancreatic cancer which is the fourth leading cause of cancer-related deaths in males, has a death rate of approximately 96 percent and in 2007 the American Cancer Society estimated that there were 37,170 new cases in the US;
- bile duct cancer affected 4,600 people in the US in 2007 and, as with pancreatic cancer, is associated with a poor prognosis and has limited treatment options;
- melanoma accounts for only 3% of all skin cancers but is responsible for more than 77% of skin cancer deaths worldwide, with approximately 60,000 people in the US in 2007 developing malignant melanoma.

***Triphendiol goes into Phase II human trials later this year and now has a number of options as to the targeted disease.***

***Those seeking more information about the phenoxodiol trial should visit***

[www.OVATUREtrial.com](http://www.OVATUREtrial.com)

***Exciting scientific results on Novogen's anticancer compound NV-128 were presented at a major cancer research meeting in the US in April, see***

[www.novogen.com](http://www.novogen.com)

## Glycotex Inc - Phase II in the US

**Glycotex** is focused on the discovery and development of therapies intended to accelerate human wound healing and tissue repair.

Its lead compound, **GLYC-101**, has already completed a Phase II human clinical trial in Australia for the treatment of chronic venous stasis ulcers and it is also aimed at applications including burn wounds, post surgical wounds and diabetic ulcers.

In the US, GLYC-101 has received approval from the FDA for its 'Investigational New Drug Application', and Glycotex has completed enrolment of a Phase IIa clinical trial in the US, using GLYC-101 as a topical administration for the treatment of burn wounds, its first targeted indication.

See [www.Glycotexinc.com](http://www.Glycotexinc.com) for more on the technology and mode of action of GLYC-101.

## Updates

*Novogen's management frequently broadcasts on-line interviews outlining progress. Links to these interviews are on [www.novogen.com](http://www.novogen.com) and you can listen to CEO, Christopher Naughton, presenting to the Emerging Companies On-Line Conference where he discusses plans for 2008 and an April update on <http://www.brr.com.au/asx/nrt>*

Novogen Limited  
140 Wicks Road  
North Ryde NSW 2113  
Australia

Phone: +612 9878 0088  
Fax: +612 9878 0055  
E-mail: [novogen@novogen.com](mailto:novogen@novogen.com)